GET DAILY SIGNALSKamada Ltd. (KMDA): Analyst Targets Suggest Path to +81% Upside Toward $14
Key Takeaways
- The central target used here is $14, representing the arithmetic mean of four current analyst price targets rounded from $13.75.
- The four reviewed targets span a wide range of $12 to $15, reflecting meaningful disagreement about the stock's near-term upside.
- At a recent price near $7.72, reaching $14 would require a gain of roughly 81% — a very large move relative to the stock's trading range.
- Supporting factors include record nine-month revenue, rising margins, a strong cash position, and a unanimous Buy rating from covering analysts.
- The biggest risks are the stock's low trading volume, its large gap to prior highs, and valuation that depends on sustained earnings growth.
- For more detail, explore the stock's Major News, Today's Price Move, Forecast, and Earnings pages.
Analyst Price Targets and Consensus View
Four current analyst price targets were reviewed for this analysis. The arithmetic mean is $13.75, which rounds to a $14 central target, with an approximate range of $12 to $15. When I looked at the spread across firms, I also checked this using Tickeron’s AI Screener to see how KMDA stacks up against peers in the sector.
Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating and raised the target from $11 to $12 in early November 2026. H.C. Wainwright's Andrew Fein maintained a Buy and a $13 target in September 2026, after raising it from $11 late in 2025. Benchmark's Robert Wasserman has repeatedly maintained a Buy with a $15 target, and William Blair set a $15 price objective in mid-2026.
The spread between $12 and $15 is notable. The higher targets from Benchmark and William Blair appear to reflect confidence in Kamada's plasma-therapy franchise and improving profitability, while the more conservative figures from Stifel and H.C. Wainwright suggest caution about the speed of a re-rating. All four analysts rate the stock a Buy, so the disagreement is about magnitude, not direction. This mean is a calculation, not an official published consensus, and should not be read as a guarantee.
Current Market Position and Path Toward the Target
As of early November 2026, KMDA traded near $7.72, with a market capitalization of roughly $444 million and a trailing P/E ratio near 20. The stock's 52-week range is approximately $6.60 to $9.35, meaning the shares sit in the lower-middle portion of their recent range.
Reaching $14 would require an upside of roughly 81% from $7.72 — a very large move that would take the stock roughly 50% above its 52-week high of $9.35. Such a path would likely depend on a combination of sustained double-digit revenue growth, continued margin expansion, and a broader re-rating of the shares by institutional investors, rather than any single catalyst.
What Could Support a Move Toward the Target
Kamada reported record nine-month revenue of $152.2 million for 2026, up 12% year over year, with third-quarter revenue of $52 million, up 11%. Net income for the quarter rose 51% to $8 million, or $0.14 per diluted share, while adjusted EBITDA climbed 30% to $15.2 million. The company held about $75.3 million in cash and short-term investments at the end of September 2026 and continues to pay a cash dividend, underscoring its ability to convert profit into cash flow.
Growth is being driven by demand for KEDRAB, Varizig, and HepaGam, along with a distribution segment that grew 35% in the quarter. A supply agreement with Kedrion running through 2031 and the company's vertical integration into plasma collection support a multi-year demand outlook. Analysts' unanimous Buy ratings reflect confidence that this fundamental momentum can justify a higher valuation. I’m watching this closely because the earnings trajectory looks solid on paper.
What Could Prevent the Target From Being Reached
The principal obstacle is scale. A move from $7.72 to $14 is not a small step for a company with a market value below $500 million and relatively modest trading volume, which can amplify volatility. The target also sits far above the stock's 52-week high, meaning the market has not yet validated a sustained move beyond $9.35.
Other risks include competition in plasma-derived therapies, reliance on a concentrated product portfolio, foreign-exchange exposure given the company's Israel-based operations, and the possibility that earnings growth slows or margins compress. A broader rotation away from small-cap or healthcare names, or any setback in commercial execution, could also keep the shares range-bound.
Technical Levels and Market Structure
The stock's 52-week high near $9.35 represents a meaningful resistance level that the shares would first need to reclaim and hold. The $6.60 area marks the lower end of the recent range and serves as a support level. The $14 target sits well above both, implying that a durable breakout beyond prior highs would be a prerequisite for the move analysts envision.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms may differ. Investors should watch quarterly earnings and revenue growth, gross-margin trends, any updates to full-year guidance, dividend declarations, and changes to analyst targets. Developments in the KEDRAB franchise, the Kedrion partnership, and plasma-collection capacity are also key, as are broader small-cap and healthcare sector flows.
Using Tickeron’s AI Daily Buy/Sell Signals
Traders looking to time entries and exits around KMDA can use Tickeron’s AI Daily Buy/Sell Signals. In my view, the system helps by applying artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. This has been useful for me when evaluating opportunities alongside the fundamental picture for KMDA.
Final Assessment
The $14 central target reflects the average of four current analyst price targets, rounded from $13.75, against a range of $12 to $15. From a recent price near $7.72, that implies a very large required move of about 81%. The bull case rests on record revenue, expanding margins, a strong balance sheet, and a unanimous Buy rating, while the bear case centers on the stock's small size, modest liquidity, and a target far above its 52-week high. Whether KMDA approaches $14 will likely depend on sustained earnings momentum and a genuine re-rating by investors — neither of which is guaranteed. From what I see, this remains a story worth following closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KMDA's Stochastic Oscillator stays in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KMDA's RSI Oscillator exited the oversold zone, 12 of 17 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
Following a +3.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where KMDA advanced for three days, in 174 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
KMDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KMDA as a result. In 69 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 68%.
The Moving Average Convergence Divergence Histogram (MACD) for KMDA turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 33 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
KMDA moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for KMDA crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KMDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
The Aroon Indicator for KMDA entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.548) is normal, around the industry mean (7.271). P/E Ratio (19.026) is within average values for comparable stocks, (0.479). Projected Growth (PEG Ratio) (0.644) is also within normal values, averaging (2.202). Dividend Yield (0.094) settles around the average of (0.061) among similar stocks. P/S Ratio (2.487) is also within normal values, averaging (181.047).
The Tickeron Seasonality Score of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 48 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. KMDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in pharmaceutical business
Industry PharmaceuticalsGeneric